Ab&B Bio-Tech Co., Ltd. (JS) (2627)

Overview

Ab&B Bio-Tech Co., Ltd. (JS) is a China-based biotechnology enterprise that specializes in the research, development, manufacturing, and commercialization of advanced human vaccines. Established in 2015 and headquartered in Taizhou, Jiangsu Province, the company is committed to enhancing public health by creating innovative vaccine technologies that align with international standards. Ab&B Bio-Tech operates research and development centers located in Shanghai and Taizhou, equipped with pilot platforms to facilitate the advancement of its diverse product pipeline. The company maintains production facilities that comply with Good Manufacturing Practices (GMP), ensuring full-cycle development from initial innovation through to market delivery. Primarily catering to the domestic market, Ab&B Bio-Tech plays a crucial role in addressing public health needs through its effective vaccination solutions.

Products and Services

• Quadrivalent Subunit Influenza Vaccine: This commercially available vaccine targets four distinct influenza virus strains and is designed for individuals aged three and older. It aims to provide effective protection during flu seasons.
• Lyophilized Human Rabies Vaccine Candidate: In the pipeline, this vaccine candidate is intended to prevent rabies, a potentially fatal viral disease, showcasing the company's commitment to addressing infectious diseases.
• Viral Vaccines: Ab&B Bio-Tech is developing a range of vaccines targeting various viral infections, contributing to comprehensive immunization strategies against prevalent viruses.
• Bacterial Vaccines: The company is also engaged in the creation of vaccines that combat bacterial pathogens, further expanding its therapeutic capabilities.
• Conjugate Vaccines: These vaccines are designed to enhance the body's immune response, particularly in young children, by linking polysaccharides from bacteria to a protein carrier.
• Recombinant Subunit Vaccines: Utilizing recombinant DNA technology, these vaccines focus on producing specific antigens to stimulate an immune response without using the live virus or bacterium.
• mRNA Vaccines: By harnessing the power of messenger RNA technology, Ab&B Bio-Tech is developing vaccines that instruct cells to produce proteins that trigger an immune response against specific pathogens.